Secukinumab is a selective, high affinity, fully-humanised monoclonal antibody against IL17A, a cytokine with a key role in several immunoinflammatory disorders. Secukinumab has been approved by the Food and Drug Administration, U.S. as a 150 mg or 300 mg subcutaneous preparation for the treatment of psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (Ax-SPA). In agreement with our rheumatology colleagues, anti-IL17A therapy with secukinumab was started at the dosage of 150 mg in axSpA patients and 300 mg in the PsA patient, in combination with MTX 15 mg weekly. [Extracted from the article]